A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 12
- Registration Number
- NCT06149559
- Locations
- ๐ต๐ฑ
Mg0006 40155, Warszawa, Poland
๐บ๐ธMg0006 50574, Denton, Texas, United States
๐ฎ๐นMg0006 40290, Bologna, Italy
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 8
- Registration Number
- NCT06055959
- Locations
- ๐ฌ๐ง
Mg0014 40736, London, United Kingdom
๐ฐ๐ทMg0014 20220, Seoul, Korea, Republic of
๐บ๐ธMg0014 50168, Chicago, Illinois, United States
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 207
- Registration Number
- NCT06055985
- Locations
- ๐บ๐ธ
Pd0060 50580, Miami, Florida, United States
๐บ๐ธPd0060 50597, Naples, Florida, United States
๐บ๐ธPd0060 50591, Ocala, Florida, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Chronic Plaque PsoriasisModerate to Severe Chronic Plaque Psoriasis
- Interventions
- Other: Placebo
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 133
- Registration Number
- NCT06011733
- Locations
- ๐จ๐ณ
Ps0041 20308, Shanghai, China
๐จ๐ณPs0041 20117, Guangzhou, China
๐จ๐ณPs0041 20310, Ningbo, China
A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
- Conditions
- Healthy Study Participants
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 73
- Registration Number
- NCT05845645
- Locations
- ๐บ๐ธ
Up0073 10001, Glendale, California, United States
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 62
- Registration Number
- NCT05681715
- Locations
- ๐ท๐ธ
Mg0020 40729, NIS, Serbia
๐บ๐ธMg0020 50099, San Francisco, California, United States
๐ฎ๐นMg0020 40150, Roma, Italy
A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 63
- Registration Number
- NCT05643794
- Locations
- ๐ฌ๐ง
Fm0001 4402, Manchester, United Kingdom
๐ฌ๐งFm0001 4405, Blackpool, United Kingdom
๐ฌ๐งFm0001 4406, Cannock, United Kingdom
A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 21
- Registration Number
- NCT05626439
- Locations
- ๐บ๐ธ
Up0104 1001, Baltimore, Maryland, United States
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Minzasolmin (UCB0599)
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 374
- Registration Number
- NCT05543252
- Locations
- ๐ช๐ธ
Pd0055 40540, Madrid, Spain
๐ช๐ธPd0055 40542, Mรณstoles, Spain
๐ช๐ธPd0055 40352, Pamplona, Spain
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 26
- Registration Number
- NCT05514873
- Locations
- ๐บ๐ธ
Mg0017 50593, Rancho Mirage, California, United States
๐บ๐ธMg0017 50304, Dallas, Texas, United States
๐บ๐ธMg0017 50086, Charlotte, North Carolina, United States